Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma
Survivin is an anti-apoptotic protein that is highly expressed in many cancers, including malignant gliomas. Preclinical studies established that the conjugated survivin peptide mimic SurVaxM (SVN53-67/M57-KLH) could stimulate an anti-tumor immune response against murine glioma in vivo, as well as h...
Main Authors: | Fenstermaker, Robert A., Ciesielski, Michael J., Qiu, Jingxin, Yang, Nuo, Frank, Cheryl L., Lee, Kelvin P., Mechtler, Laszlo R., Belal, Ahmed, Ahluwalia, Manmeet S., Hutson, Alan D. |
---|---|
Format: | Online |
Language: | English |
Published: |
Springer Berlin Heidelberg
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069322/ |
Similar Items
-
Papillary tumor of the pineal region with extended clinical and radiologic follow-up
by: Shakir, Hakeem J., et al.
Published: (2015) -
Survivin and gliomas: A literature review
by: Varughese, Rosilin Kotakkathu, et al.
Published: (2016) -
Survivin as a Potential Mediator to Support Autoreactive Cell Survival in Myasthenia Gravis: A Human and Animal Model Study
by: Kusner, Linda L., et al.
Published: (2014) -
Structure of RiVax: a recombinant ricin vaccine
by: Legler, Patricia M., et al.
Published: (2011) -
Computational vaccinology and the ICoVax 2012 workshop
by: He, Yongqun, et al.
Published: (2013)